---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-028403"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:49:07.177318+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health adopts 1-year rights plan after receiving acquisition interest

## Summary
- Board adopted limited-duration rights plan on Feb 26, 2025; expires Feb 26, 2026.
- Rights trigger at 20% beneficial ownership of voting stock; holders can buy shares at $4.50 for twice the market value.
- Jaguar received indication of interest to acquire the company; plan aims to discourage open-market accumulation without a premium.
- First proof-of-concept IIT results for crofelemer in SBS-IF and MVID expected Q2 2025; FDA meeting on breast cancer subgroup results also Q2.
- Record date for rights dividend is March 10, 2025.

## SEC filing metadata
- accession: 0000950170-25-028403
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000095017025028403/0000950170-25-028403-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000095017025028403/jagx-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-028403
- JSON: https://secwatch.observer/filing/0000950170-25-028403.json
- Plain text: https://secwatch.observer/filing/0000950170-25-028403.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.